Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
595.40
+4.27 (+0.72%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 1, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
388,667
Open
587.76
Bid (Size)
593.80 (1)
Ask (Size)
596.99 (1)
Prev. Close
591.13
Today's Range
586.17 - 597.00
52wk Range
538.01 - 747.42
Shares Outstanding
91,779,465
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
Top News
More News
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
July 01, 2022
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.
Via
Benzinga
U.S. FDA Accepts Regeneron's Diabetic Retinopathy Candidate Submission For Review
June 29, 2022
The U.S. Food and Drug Administration (FDA) has accepted Regeneron Pharmaceuticals’ (NASDAQ: REGN) supplemental Biologics License Application (sBLA) of EYLEA (aflibercept) Injection for review in...
Via
Benzinga
Performance
YTD
-5.06%
-5.06%
1 Month
-5.54%
-5.54%
3 Month
-14.75%
-14.75%
6 Month
-5.06%
-5.06%
1 Year
+2.26%
+2.26%
More News
Read More
From Axcella To Tonix, Here Are The Penny Stocks Of Companies Working On Long Covid
June 27, 2022
Via
Investor's Business Daily
Intellia's Gene-Editing Candidate Shows Durability In ATTR Amyloidosis
June 24, 2022
Via
Benzinga
FDA Accepts Regeneron, Sanofi's Filing For Review In Skin Disease
May 31, 2022
Via
Benzinga
Regeneron's Evkeeza Reduces Bad Cholesterol By 48% In Children Aged 5-11 Years
May 23, 2022
Via
Benzinga
Regeneron Pharmaceuticals Whale Trades Spotted
June 17, 2022
Via
Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $4,800 Today
June 15, 2022
Via
Benzinga
Regeneron Pharmaceutical Stock Sees RS Rating Jump To 82
June 08, 2022
Via
Investor's Business Daily
The Daily Biotech Pulse: FDA Adcomm Backing For Novavax's COVID-19 Shot, New Data On Moderna's Omicron Vaccine, DBV Tech's Encouraging Peanut Allergy Trial Data
June 08, 2022
Via
Benzinga
Sunshine Biopharma States It Is Developing COVID Antiviral That Could Play Important Role In Treating Endemic COVID
June 08, 2022
Via
Benzinga
U.S. FDA Approves Regeneron And Sanofi's Lead Drug For Skin Inflammation In Children
June 07, 2022
Via
Benzinga
The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More
June 05, 2022
Via
Benzinga
Stock Market Rally Falls As Fed Signals More Big Rate Hikes; Salesforce, Tesla In Focus: Weekly Review
June 03, 2022
Via
Investor's Business Daily
Markets Rise Amid Strength In Tech, Software
June 02, 2022
Via
Benzinga
Regeneron Pharmaceuticals Dives On $1.1 Billion Deal To Rival Merck In Cancer
June 02, 2022
Via
Investor's Business Daily
Regeneron Pharmaceuticals Whale Trades Spotted
June 02, 2022
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May 31, 2022
Via
Benzinga
7 Analysts Have This to Say About Regeneron Pharmaceuticals
May 31, 2022
Via
Benzinga
NASDAQ:REGN Investor Notice: Investigation over Potential Wrongdoing at Regeneron Pharmaceuticals, Inc.
May 31, 2022
Via
SBWire
As COVID Subsidies, Here are 8 Infectious Diseases That Could Emerge As Potent Threats
May 30, 2022
Via
Benzinga
United Airlines Leads Five Stocks Breaking Resistance As Market Rebounds
May 28, 2022
Via
Investor's Business Daily
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
May 22, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022
May 23, 2022
Via
Benzinga
FDA Approves Regeneron and Sanofi's Dupixent (dupilumab) For Eosinophilic Esophagitis (EoE) Ahead of Schedule
May 20, 2022
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.